Premium
Cancer Immunomics
Author(s) -
HARDOUIN JULIE,
LASSERRE JEANPAUL,
SYLVIUS LOÏK,
JOUBERTCARON RAYMONDE,
CARON MICHEL
Publication year - 2007
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1196/annals.1381.024
Subject(s) - autoantibody , proteome , proteomics , antigen , cancer , breast cancer , colorectal cancer , computational biology , microbiology and biotechnology , affinity chromatography , chemistry , biology , antibody , biochemistry , enzyme , immunology , genetics , gene
Cancer remains one of the leading causes of death worldwide. Thus, to identify any useful biomarkers is still a need. We performed “cancer immunomics” to identify autoantibody signatures produced in response to the presence of either breast or colorectal cancer. SERological proteome analysis (SERPA) was performed by two‐dimensional (2‐D) electrophoresis separation, immunoblotting, image analysis, and mass spectrometry. Alternatively, to identify the antigens recognized by the autoantibodies of cancer patients, we developed an approach combining 2‐D immunoaffinity chromatography, enzymatic digestion of the isolated antigens, nano flow separation of the resulting peptides, and identification: MAPPing (multiple affinity protein profiling). By these approaches we identified both proteins recognized by autoantibodies independently of a cancer status, and a limited number of proteins reacting preferentially with cancer sera.